Monthly research recap
PTSD research: September 2026
What September 2026's 11 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research indexed in September 2026 on PTSD points in a broadly positive direction for several interventions, but with important caveats. A meta-analysis of seven RCTs found MDMA-assisted psychotherapy may improve core PTSD symptoms, dissociation, depression, and functional impairment, though not sleep; a 171-person RCT found dronabinol reduced nightmare frequency and intensity versus placebo; and a 141-person RCT found a digital nonattachment intervention outperformed waitlist at 8 and 20 weeks. Evidence is limited by small samples, blinding difficulties, a common sponsor across MDMA trials, and, for dronabinol, more serious adverse events than placebo and untested long-term safety.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | Supports | Across seven randomized controlled trials, MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment versus low-dose MDMA or placebo plus psychotherapy, but not sleep quality. | |
| Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial. 2026 | randomized controlled trial | 171 | Supports | Dronabinol (2.5-15 mg nightly for 10 weeks) reduced CAPS-IV B2 nightmare frequency and intensity more than placebo (between-group difference -1.50; Cohen's d = 0.65; P < 0.001), with serious adverse events in 8.0% of dronabinol patients versus none on placebo. |
| Efficacy of a Digital Nonattachment-Based Intervention for Post-traumatic Stress Symptoms: A Randomised Controlled Trial 2026 | randomized controlled trial | 141 | Supports | A self-guided digital nonattachment intervention produced significantly greater reductions in PTSD symptoms than waitlist at 8 and 20 weeks, with large between-group effect sizes and increased nonattachment and reduced psychological inflexibility. |
| Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder. 2026 | pilot trial | Supports | MDMA-enhanced cognitive-behavioral conjoint therapy was feasible and acceptable and was associated with clinically meaningful reductions in PTSD symptoms and improvements in relationship satisfaction. | |
| Mindfulness-Based Interventions for Nurses: A Meta-Analysis of Effects on Compassion Fatigue, Job Burnout, and Traumatic Stress. 2026 | systematic review and meta-analysis | 578 | Supports | Across seven randomized controlled trials, mindfulness-based interventions were associated with significant reductions in compassion fatigue (SMD -1.11), job burnout (SMD -0.89), and traumatic stress (SMD -0.99), though the authors conclude evidence is insufficient to support routine implementation as an independent workforce intervention. |
| Mindfulness and Posttraumatic Stress Symptoms in Mothers of Children With Pediatric Cancer 2026 | cross-sectional survey | 53 | Supports | Higher mindfulness was associated with lower posttraumatic stress symptoms (B = -0.88, p < 0.001), with the acting-with-awareness and non-judgment domains each linked to lower symptoms. |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues that MDMA-assisted psychotherapy has the largest phase 3 dataset in PTSD but was declined FDA approval in 2024 on ethical grounds, and that certainty of evidence remains low or very low for several indications, so psychedelics should be considered experimental treatments. | |
| 717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD 2026 | literature review | Unclear | Argues that MDMA-assisted therapy trials raise distinctive ethical issues because MDMA's affective and cognitive effects may heighten patient vulnerability, alter memory and beliefs, and complicate informed consent, requiring systematic attention to consent, therapist training, boundary management, and risk monitoring. | |
| Recommending Meditation in Complex PTSD: Clinical Considerations 2026 | review | Unclear | Argues that because CPTSD involves elevated dissociation, childhood adversity, and shame vulnerabilities linked to meditation-related adverse events, standard PTSD screening tools may miss patients needing enhanced informed-consent discussions, and proposes validated screening, trauma-informed consent, and evidence-informed technique selection. | |
| The Nova Protocol: a comprehensive multimodal longitudinal study among civilian survivors of a mass trauma event. 2026 | longitudinal observational study protocol | Unclear | Describes the rationale, design, and methodology of a multimodal longitudinal observational study of civilian mass-trauma survivors, stating that naturalistic, self-selected psychoactive substance exposure means findings will be interpreted as mechanistic and prognostic associations rather than causal effects. | |
| A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials 2026 | systematic review | Mixed | Across 75 placebo-controlled studies, MDMA reliably enhanced subjective social experience (sociability, emotional openness, closeness, emotional empathy), but behavioural prosociality such as cooperation and trust was inconsistent and context dependent, and accuracy in identifying negative social cues was reduced. |
Points of agreement
- Multiple controlled and meta-analytic studies report symptom improvement for PTSD with MDMA-assisted psychotherapy, dronabinol, and a digital nonattachment intervention.
- Mindfulness-based approaches are consistently associated with lower posttraumatic or traumatic stress symptoms in the populations studied.
- Reviewers repeatedly flag methodological limits: small samples, blinding challenges, non-standardized therapies, and a common sponsor across MDMA trials.
- Ethical and consent concerns are raised as central to translating MDMA-assisted therapy into practice.
Conflicts
- One review characterizes MDMA-assisted psychotherapy as having the largest phase 3 PTSD dataset yet notes FDA declined approval on ethical grounds and rates certainty of evidence low or very low, while a meta-analysis reports significant improvements across PTSD, dissociation, depression, and functional impairment.
- MDMA's effects on social cognition are described as reliable for subjective experience but inconsistent for behavioural prosociality, indicating domain-dependent rather than uniform effects.
Gaps
- Long-term durability and safety of dronabinol for PTSD nightmares are untested, and serious adverse events were more frequent than placebo.
- Blinding integrity and independence from sponsor influence remain unresolved in MDMA-assisted therapy trials.
- Most evidence comes from small samples; larger multicenter randomized controlled trials are called for, particularly for mindfulness-based interventions.
- Whether reduced accuracy for negative social cues reflects perceptual blunting or response bias has not been tested with signal-detection methods.
- CPTSD-specific screening and meditation safety in trauma populations lack validated tools and prospective data.
- Prospective longitudinal mechanisms after civilian mass trauma are only now being studied, with causal inference precluded by naturalistic substance exposure.